EGFR and non-small cell lung carcinoma: Gefitinib (Iressa): This epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor is indicated only for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.